



Pain in the cancer patient: different pain characteristics CHANGE pharmacological treatment requirements

Gerhard Müller-Schwefe, Karsten Ahlbeck, Dominic Aldington, Eli Alon, Stefano Coaccioli, Flaminia Coluzzi, Frank Huygen, Wolfgang Jaksch, Eija Kalso, Magdalena Kocot-Kępska, Hans-Georg Kress, Ana Cristina Mangas, Cesar Margarit Ferri, Bart Morlion, Andrew Nicolaou, Concepción Pérez Hernández, Joseph Pergolizzi, Michael Schäfer & Patrick Sichère

To cite this article: Gerhard Müller-Schwefe, Karsten Ahlbeck, Dominic Aldington, Eli Alon, Stefano Coaccioli, Flaminia Coluzzi, Frank Huygen, Wolfgang Jaksch, Eija Kalso, Magdalena Kocot-Kępska, Hans-Georg Kress, Ana Cristina Mangas, Cesar Margarit Ferri, Bart Morlion, Andrew Nicolaou, Concepción Pérez Hernández, Joseph Pergolizzi, Michael Schäfer & Patrick Sichère (2014) Pain in the cancer patient: different pain characteristics CHANGE pharmacological treatment requirements, *Current Medical Research and Opinion*, 30:9, 1895-1908, DOI: [10.1185/03007995.2014.925439](https://doi.org/10.1185/03007995.2014.925439)

To link to this article: <http://dx.doi.org/10.1185/03007995.2014.925439>



Accepted author version posted online: 19 May 2014.
Published online: 10 Jun 2014.



Submit your article to this journal [↗](#)



Article views: 753



View related articles [↗](#)



View Crossmark data [↗](#)

Commentary

Pain in the cancer patient: different pain characteristics CHANGE pharmacological treatment requirements

Gerhard Müller-Schwefe

Schmerz- und Palliativzentrum, Göppingen, Germany

Karsten Ahlbeck

Capio S:t Görans Hospital, Stockholm, Sweden

Dominic Aldington

Hampshire Hospitals NHS Trust, Winchester, Hants, UK

Eli Alon

Universitätsspital Zurich, Zurich, Switzerland

Stefano Coaccioli

Santa Maria General Hospital, Terni, Italy

Flaminia Coluzzi

Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Italy

Frank Huygen

University Hospital, Rotterdam, The Netherlands

Wolfgang Jaksch

Wilhelminenspital der Stadt Wien, Austria

Eija Kalso

Helsinki University Central Hospital, Finland

Magdalena Kocot-Kępska

Department of Pain Research and Treatment, Collegium Medicum Jagiellonian University, Kraków, Poland

Hans-Georg Kress

Department of Special Anaesthesia and Pain Therapy, Medizinische Universität/AKH Wien, Vienna, Austria

Ana Cristina Mangas

Hospital de Santo André, Leiria, Portugal

Cesar Margarit Ferri

Hospital General Universitario de Alicante, Spain

Bart Morlion

University Hospitals Leuven, Belgium

Andrew Nicolaou

St. Georges Hospital, London, UK

Abstract

Twenty years ago, the main barriers to successful cancer pain management were poor assessment by physicians, and patients' reluctance to report pain and take opioids. Those barriers are almost exactly the same today. Cancer pain remains under-treated; in Europe, almost three-quarters of cancer patients experience pain, and almost a quarter of those with moderate to severe pain do not receive any analgesic medication. Yet it has been suggested that pain management could be improved simply by ensuring that every consultation includes the patient's rating of pain, that the physician pays attention to this rating, and a plan is agreed to increase analgesia when it is inadequate. After outlining current concepts of carcinogenesis in some detail, this paper describes different methods of classifying and diagnosing cancer pain and the extent of current under-treatment. Key points are made regarding cancer pain management. Firstly, the pain may be caused by multiple different mechanisms and therapy should reflect those underlying mechanisms – rather than being simply based on pain intensity as recommended by the WHO three-step ladder. Secondly, a multidisciplinary approach is required which combines both pharmacological and non-pharmacological treatment, such as psychotherapy, exercise therapy and electrostimulation. The choice of analgesic agent and its route of administration are considered, along with various interventional procedures and the requirements of palliative care. Special attention is paid to the treatment of breakthrough pain (particularly with fast-acting fentanyl formulations, which have pharmacokinetic profiles that closely match those of breakthrough pain episodes) and chemotherapy-induced neuropathic pain, which affects around one third of patients who receive chemotherapy. Finally, the point is made that medical education should place a greater emphasis on pain therapy, both at undergraduate and postgraduate level.

Introduction

In a recent pan-European survey of cancer patients, the most common reason for the initial consultation that led to the cancer diagnosis was pain (Figure 1)¹. Studies have found that pain is experienced by 25–30% of patients with recently diagnosed cancers², by over 80% of patients with advanced metastatic disease³, and that approximately 50% of hospitalized cancer patients experience untreated pain during the last 3 days of life⁴. Importantly, the impact of this pain on the quality of life can be devastating; cancer patients with pain report significantly lower levels of performance status and higher levels of total mood disturbance than those who are pain-free, as well as significantly more anger, fatigue, depression, confusion, and lethargy⁵. However – and despite the fact that World Health Organization (WHO) guidelines for the management of cancer pain were published more than two decades ago⁶ – there is a substantial body of evidence which indicates that the treatment of cancer pain is often suboptimal^{1,7–9}.

Concepción Pérez Hernández

Hospital Universitario de la Princesa, Madrid, Spain

Joseph PergolizziDepartment of Medicine, Johns Hopkins University
School of Medicine, Baltimore, MD, USA
Naples Anesthesia and Pain Associates, Naples,
FL, USA**Michael Schäfer**Department of Anaesthesiology and Intensive Care
Medicine, Charité University Berlin, Campus Virchow
Klinikum, Berlin, Germany**Patrick Sichère**

Hôpitaux de Saint-Denis, Paris, France

Address for correspondence:Joseph Pergolizzi MD, Professor, Naples Anesthesia
and Pain Associates, 4840 Sycamore Drive, Naples,
FL 34119, USA.Tel.: +1 239 597 3564; Fax: +1 239 597 7566;
jpjmd@msn.com**Keywords:**Breakthrough pain – Causative mechanisms –
Chemotherapy-induced neuropathic pain – Fast-
acting fentanyl formulations – Multidisciplinary
approach – Opioids – Under-treatment

Accepted: 9 May 2014; published online: 10 June 2014

Citation: *Curr Med Res Opin* 2014; 30:1895–908**Consensus points**The impact of cancer pain on quality of life can be devastating.
The treatment of cancer pain is often suboptimal.

The CHANGE PAIN Advisory Board of leading pain specialists from Europe and the USA has met regularly since 2009 to discuss issues related to the physiology and treatment of pain. Its main objectives are to increase the understanding of pain among the wider medical community, and to improve pain management by disseminating its conclusions and providing guidance to other clinicians. On March 30th and 31st, 2012, the Board met in Düsseldorf to review various aspects of the development and current treatment of cancer pain, and then considered specific topics in more detail.

Development of cancer and cancer pain

The neurobiology of cancer pain is best understood by summarizing current concepts of carcinogenesis. The initial change is a number of mutations occurring in a cell over time. These may be caused by hereditary or biological factors, or by exposure to physical or chemical agents, and they have a cumulative effect. Certain types of gene – such as proto-oncogenes and tumor-suppressor genes – play a key role in the transformation of a normal cell into a cancer cell, which ignores signaling mechanisms that instruct it to stop dividing, become specialized, or undergo apoptosis¹⁰. Typically, this is followed by pre-malignant cellular proliferation which is usually reversible and may include: hyperplasia (abnormal increase in the number of cells), hypertrophy (abnormal increase in the size of cells), or dysplasia (alteration in the size, shape and organization of the cellular components of a tissue). These cells are generally well differentiated and function similarly to the tissue from which they arose. Progression to ‘cancer in situ’ and then invasive cancer is accompanied by a gradual change in appearance and loss of physiological functions, as the cells divide haphazardly and accumulate into a non-structured tumor. These later stages are almost always irreversible and are characterized by the capacity to invade healthy tissue, both locally and in distant organs, via blood and lymphatic vessels.

Some cancer pain arises from within the cancer microenvironment¹¹. The key cellular components here are primary afferent nociceptors, immune cells and the cancer cells, which produce and secrete mediators that modulate nociception. These mediators include endothelin-1 (ET-1), protons, proteases, nerve growth factor (NGF), bradykinin and tumor necrosis factor alpha (TNF α), which have an effect on primary afferent nociceptors to produce pain¹¹.

Low pH is characteristic of the cancer microenvironment, reflecting the elevated metabolic rates and anaerobic conditions that occur with carcinogenesis. This acidosis induces the expression of acid-sensing ion channels (ASICs) and is a well established cause of pain¹¹. ET-1 produces nociceptive behavior^{12,13} and drives cancer pain¹⁴ by binding to G-protein coupled receptors that differentially affect opioid release from tumors. For example, there is evidence that an allelic substitution of adenine by guanine in position 118 (A118G) of the μ -opioid receptor gene (OPRM1) has an effect on angiogenesis and tumor growth¹⁵. The nociceptive effect of protons is produced by direct activation of the transient receptor potential vanilloid-1 (TRPV-1) channel, a Ca²⁺-permeable ionotropic receptor. Proteolytic activity plays a major role in carcinogenesis and cancer pain; protease activated receptors (PARs) are present on primary afferent nociceptors and are activated either directly by proteases or




Figure 1. Reasons for consulting a healthcare professional that led to a diagnosis of cancer¹. By permission of Oxford University Press.

by their peptide products. NGF is normally secreted to promote the local growth and survival of afferent sensory neurons, but its secretion into the microenvironment by cancer cells leads to a number of changes that produce pain, including modulation of inflammatory cell activity. Certain cancers secrete kallikrein, which increases the concentration of bradykinin in the microenvironment¹⁶. Bradykinin appears to have a direct nociceptive effect in cancer pain, since blockade of the bradykinin B₁ receptor reduces bone cancer pain¹⁷, but it also induces increased expression and secretion of ET-1¹⁸. High levels of proinflammatory cytokines are produced in cancer and TNF α stimulates immune cells, which can produce nociceptive agents that interact with primary afferent nociceptors¹⁹. In addition, a direct local role for TNF α in the production of both mechanical and heat hyperalgesia has been demonstrated in animal models^{20,21}.

Inflammation is a key component of the tumor microenvironment and inflammation-mediated tumor progression is produced by transcription factors, cytokines, chemokines and infiltrating leukocytes²². By directly or indirectly downregulating DNA repair pathways and cell cycle checkpoints, these inflammatory mediators produce a genomically heterogeneous population of expanding cells naturally selected for their ability to proliferate, invade and evade host defenses. A particularly

insidious form of tumor growth is perineural invasion; i.e. the spread and proliferation of cancer within a nerve. This process is associated with NGF²³, linked to both pain and recurrence following surgical resection^{24,25}, and also indicates poor prognosis and reduced survival rates^{25,26}. Early symptoms may include pain, burning sensations, paresthesias, numbness and formication²⁷, although the patient may be asymptomatic at first. Motor weakness is a late sign²⁷, while complete denervation may produce muscle atrophy. Perineural involvement is emerging as an important pathological feature of many malignancies, including those of the pancreas, colon and rectum, prostate, head and neck, biliary tract, and stomach²⁸.

Often, the first symptom for which patients consult a physician is pain from bone metastasis²⁹. This is a multi-step process which includes the following sequence of events: (I) tumor growth, detachment of cancer cells and invasion of the tissue stroma; (II) neoangiogenesis; (III) escape from the tissue by intravasation; (IV) survival in the circulation; (V) chemoattraction and arrest (docking and locking) in the bone marrow endothelial vessel wall; (VI) extravasation; and (VII) establishment of the metastatic microenvironment via the cross-talk between the cancer and bone cells³⁰⁻³². Cyclooxygenase-2 (COX-2) is thought to play a major role in this process;

over-expression leads to increased tumor formation and pharmacological suppression of COX-2 inhibits metastasis.

Pain may arise not only from the presence of many different factors in the microenvironment, as previously described, but also from one or more of the following: nerve root infiltration, nerve compression, microfractures, stretching of the periosteum, increased intraosseous pressure and muscle spasm³³. However, a significant portion of the pain seems to be related to osteoclastic bone resorption³⁴, and animal studies have demonstrated the involvement of both peripheral sensitization, as a result of physiological and morphological changes to primary afferent fibers³⁵, and central sensitization, by augmentation of excitatory synaptic transmission in the substantia gelatinosa which is mediated via A δ and C fibers³⁶.

Classification of cancer pain

The clinical presentation of cancer pain can vary considerably, depending upon the histology of the cancer cells, the site of the primary neoplasm, and the location of any metastases. The pain may be classified in a number of different ways; for example, according to the type of pain, its relation to the cancer, the presence of pain syndromes (e.g. bone pain syndromes, visceral pain syndromes, post-chemotherapy pain syndromes), or the incidence and duration.

Pain type

In addition to the distinction between acute and chronic pain, pain syndromes can be divided into three classes according to their clinical features and etiology³⁷. Nociceptive pain is caused by the activation of peripheral A δ and C fibers (high-threshold nociceptor neurons) that respond only to noxious thermal, mechanical or chemical stimuli (e.g. pinprick, ligamentous stretch). Adaptive and biologically useful, it contributes to survival by protecting the organism from injury and promoting healing when injury has already occurred. It is usually short-lived and resolves once healing is complete³⁸. Other conditions in which it is seen include arthritis, sports injuries and post-operative pain³⁹. There are two subtypes of nociceptive pain: somatic and visceral. Somatic pain involves the skin, bones and soft tissues, and characteristically is easily localized, stabbing or boring in character, and movement-dependent. Visceral pain, which involves parenchymatous organs, hollow viscera and the peritoneum, is dull, difficult to localize and colicky in nature. Patients often describe it as a diffuse or 'pressure-type' sensation.

Inflammatory pain is essentially pain which occurs when active peripheral inflammation is detected by

nociceptors, and leads to sensitization of the nociceptive system (e.g. joint pain such as facet pain).

The third class – neuropathic pain – is not adaptive, has no protective function, and represents a disease state of the nervous system. It may be defined as 'pain arising as direct consequence of a lesion or disease affecting the somatosensory nervous system'. Essentially, a maladaptive plasticity alters nociceptive signal processing, so that responses to noxious and innocuous stimuli are enhanced, and pain is felt in the absence of stimuli (e.g. radicular pain)⁴⁰. The pain may be perceived as shooting, lancinating, 'electric shock-like' or burning, and may occur spontaneously. Positive signs, such as allodynia, hyperalgesia and hyperpathia may be accompanied by negative signs such as the loss of touch, vibration, pinprick, or thermal hypoalgesia. Neuropathic pain is typically present in cases of postherpetic neuralgia, peripheral diabetic neuropathy and multiple sclerosis.

Many patients with chronic pain experience a combination of different pain types – a condition sometimes referred to as mixed pain syndrome⁴¹. For the sake of simplicity, however, in clinical practice nociceptive and inflammatory pain are grouped under the term nociceptive pain, and a distinction is only made between nociceptive and neuropathic pain. Cancer pain may be nociceptive, neuropathic, or a combination of both types.

Relation to cancer

This classification system divides cancer pain into four categories. Firstly, cancer-related pain is directly linked to carcinogenesis and is most often caused by either compression – when a tumor physically presses on an organ or body part – or by the infiltration of hollow organs, soft tissue, bones, or nerves. Soft tissue infiltration causes localized pain as a result of tissue destruction and the infiltration of pain-sensitive structures such as fascia or tendons. Metastasis to the viscera is frequently seen in cases of lung and breast cancer, and this produces poorly localized, deep-seated pain in the chest, abdomen, or pelvis. Referred pain may also be present when a peripheral nerve is involved. Between 60% and 90% of cancer patients experience cancer-related pain⁴².

Cancer-induced bone pain (CIBP) is an important example of cancer-related pain, which a review of 26 studies found to be undertreated in 43% of patients (range 8–82%)⁴³. It often results in hospice or hospital admission and is associated with a reduced quality of life, increased psychological distress and decreased physical and social functioning⁴⁴. Notably, the extent and location of bone metastases do not necessarily correlate with pain intensity⁴⁵; patients with widespread metastases may have minimal pain, and patients with few metastases may experience severe pain.

The second category, cancer-associated pain, is only indirectly linked to the patient's cancer; for example, acute pain from herpes zoster or chronic post-herpetic neuralgia (PHN) due to tumor growth induced impairment of the patient's immune system, back pain as a result of being confined to bed for long periods of time, or coughing caused by lung cancer that triggers low back pain. This affects 5–20% of cancer patients⁴².

Treatment for the disease – including diagnostic investigations, surgery, chemotherapy, or radiotherapy – leads to therapy-related pain in 10–25% of patients⁴². Surgery may produce pain as a direct result of tissue injury or indirectly following scar formation, and neuropathic pain may follow any surgical procedure. Chemotherapy may induce painful polyneuropathy and/or mucositis. Oral mucositis may produce ulceration so severe that the patient is unable to tolerate food or fluids, delaying treatment and limiting the effectiveness of cancer therapy. Radiotherapy can cause painful inflammation of any mucous membranes that are irradiated. Other examples of therapy-related pain include myelopathy after treatment of the spinal cord, and neuropathy, which may develop months or even years after irradiation of the brachial or lumbar plexus.

The final category is cancer-independent pain, in which pain is caused by conditions that were present before the cancer diagnosis or arise independently of carcinogenesis. Conditions such as rheumatoid arthritis and migraine are responsible for this category of pain in 3–10% of cancer patients⁴².

Cancer pain syndromes

Approximately three-quarters of patients with chronic cancer pain have syndromes directly related to the neoplasm⁴⁶. These may be subdivided into neuropathic syndromes (e.g. cranial neuralgias, peripheral neuropathies), visceral nociceptive syndromes (e.g. hepatic distension syndrome, peritoneal carcinomatosis), and somatic nociceptive syndromes (e.g. tumor-related bone pain, vertebral syndromes). Most of the remainder have syndromes caused by antineoplastic treatment. Again, these can be subdivided into those caused by chemotherapy (e.g. peripheral neuropathy, complex regional pain syndrome), radiotherapy (e.g. chronic radiation myelopathy, burning perineum syndrome), or surgery (e.g. post-mastectomy pain syndrome, post-thoracotomy pain syndrome and frozen shoulder, post-amputation pain). Identifying these syndromes can guide clinical assessment and treatment, clarify prognosis, allow preventive care, and provide reassurance to patients who interpret their pain as an indication of cancer progression⁴⁶.

The complex, multidimensional nature of cancer pain presents challenges for pain classification, but the Edmonton Classification System for Cancer Pain (ECS-CP) has been developed to detect the presence of complex pain syndromes and guide the management of patients with advanced cancer⁴⁷. It uses five features – pain mechanism, incident pain, psychological distress, addictive behavior and cognitive function – and simultaneously integrates them within a cohesive framework to forecast the likely time to stable pain control, analgesic regimen and opioid dosage. Its predictive value has been confirmed in a study involving over 1000 patients from 11 palliative care centers in six different countries⁴⁷. A pain syndrome was found to be present in 86% of subjects. Younger age, neuropathic pain, incident pain, psychological distress and pain intensity were independently associated with days to achieve stable pain control. Patients with neuropathic pain, incident pain, psychological distress or higher pain intensity required more adjuvants and higher final opioid doses, in contrast to those with addictive behavior who required only higher final opioid doses⁴⁷.

Incidence and duration

Following a recent study, a new clinically based classification has been proposed which is based upon the temporal characteristics and nature of the pain experience⁴⁸. Continuous pain alone, i.e. without any episodic increase in intensity, was experienced by 11% of the patient sample⁴⁸. Intermittent or non-breakthrough pain (NBP) alone was reported by 29%⁴⁸. This may be defined as episodic pain of any intensity without continuous pain and in the absence of prescribed 'around the clock' (ATC) analgesics. The three categories of NBP are incident, non-incident and mixed. Incident pain is predictable and related to a specific precipitant, which may be voluntary (e.g. eating) or involuntary (e.g. coughing), whereas non-incident pain has no apparent precipitating factor. Almost two-thirds (60%) of the patients had periods of intermittent pain superimposed upon continuous pain⁴⁸. The episodic increase in severity, or breakthrough pain (BP), has been defined by Portenoy and Hagen as "a transitory exacerbation of pain that occurs on a background of otherwise stable pain in a patient receiving chronic opioid therapy"⁴⁹. This is sub-divided similarly to NBP, but some clinicians recognize a fourth category – end of dose failure – although there is a lack of evidence for this classification⁵⁰. Patients experience intermittent pain that consistently occurs before a scheduled ATC dose, and it usually indicates that the ATC dose should be increased.

Consensus point

The various, often combined, mechanisms and different characteristics of continuous and breakthrough pain can make cancer pain management difficult.

Cancer pain – prevalence, intensity, and treatment

The European Pain in Cancer survey provided the first robust pan-European epidemiological data on cancer pain and its treatment in 2009¹. A total of 5084 adult patients from 11 European countries and Israel, with a wide range of cancers and at all stages of the disease, took part in an initial telephone interview. From these, 573 patients who had experienced pain several times a week over the previous month, and with a pain intensity of ≥ 5 on a 0–10 Numeric Rating Scale (NRS), were randomly selected for a second in-depth interview¹.

The overall incidence of pain in the survey sample ($n = 4947$) was 73%, and ranged from 53% in patients with prostate cancer to 93% in patients with pancreatic cancer (Figure 2)¹. A striking variation was seen in the proportion of patients reporting pain in different countries, from 43% in Sweden to 95% in Italy. However, this may be caused by the types of cancer being

dissimilar from one country to another, and types with the highest prevalence of pain (pancreas, bone, brain, lymphoma, lung) being over-represented in some countries (Switzerland, Israel, Italy, UK, France, and Ireland)¹. Almost a quarter (23%) of the respondents who reported an NRS score of ≥ 5 in this initial survey were receiving no analgesic medication, including 19% of those patients who experienced pain of this intensity daily or more frequently¹.

Most patients who were selected for the second interview reported that their pain was managed by either a medical oncologist (42%) or a general practitioner (19%), but the range of healthcare professionals who had this responsibility was quite diverse (Figure 3)¹. For the majority (72%) of patients, their clinician asked about their pain at most (16%) or all (56%) consultations. However, more than a fifth (22%) were never, or only occasionally, asked about their pain, while more than half (55%) proactively described their pain at each consultation, to ensure that it was taken into consideration¹. After prompting, 33% of patients recalled that their clinician had used a pain scale to measure their pain, but there were major differences between countries, with Italy (70%), France (52%), and Ireland (40%) using these instruments most frequently¹.

Although all these patients ($n = 573$) had moderate to severe pain, 11% were not receiving any analgesia and a further 8% were taking only over-the-counter (OTC) medication¹. More than a quarter (28%) of




Figure 2. Incidence of pain by cancer type (CRC = colorectal cancer, NHL = non-Hodgkin's lymphoma, SCCHN = squamous cell cancer of the head and neck)¹. By permission of Oxford University Press.




Figure 3. Healthcare provider responsible for pain management¹. By permission of Oxford University Press.

those whose pain was rated at $NRS \geq 7$ ($n = 241$) were not receiving strong opioids. Of the patient sample, 50% believed that their clinicians did not consider quality of life to be an important aspect of the overall care plan, and 12% believed their clinicians did not understand that pain was a problem. Substantial minorities believed that their clinicians would rather treat their cancer than their pain (38%) or did not know how to treat moderate to severe cancer pain (26%). Large majorities of those patients receiving prescription analgesics (84%; $n = 441$) and of those receiving strong opioids 87% ($n = 183$) rated their medication as 'quite effective' or 'very effective'¹. However, breakthrough pain was common among those receiving prescription medication, affecting 63% of the patients. The authors concluded that "poor care of cancer pain is clearly unacceptably commonplace in Europe"¹.

These results were supported by a recent survey which found that the most significant barriers to successful cancer pain management were almost exactly the same as 20 years ago – poor assessment, patients' reluctance to report pain and to take opioids – and that efforts to improve treatment have had little effect on oncologists' attitudes and practice⁵¹. It has been suggested that improving the management of cancer-related pain could be as simple as ensuring that every consultation includes the patient's rating of pain, that the oncologist pays attention to the answer, and a plan is agreed to increase analgesia when it is inadequate⁵².

Cancer pain management

General principles of treatment

The overall objective of treating cancer pain is to achieve pain relief and the highest possible quality of life for the patient. Therapy should address all elements of the patient's pain: cancer-related, cancer-associated, therapy-related, and cancer-independent. Successful management of these diverse types of pain requires a multidisciplinary approach combining both pharmacological and non-pharmacological treatment such as psychotherapy, exercise therapy, massage and electrostimulation^{53,54}. General principles include the immediate relief of acute pain and, if possible, preventing the development of chronic pain.

As pain can be caused by multiple different mechanisms, it is important that pain therapy reflects these underlying mechanisms^{55,56} and is not simply based on pain intensity, as recommended by the WHO three-step ladder. For example, bone metastases often produce a high local concentration of prostaglandins, so NSAIDs are generally effective against CIBP, because they act partly by blocking prostaglandin biosynthesis.

Also, beyond the physical distress it causes, pain may be accompanied by fear, anxiety, weakness, depression and insomnia. By explaining the causes of pain and the treatment options to the patient in straightforward terms, these symptoms can be alleviated, quality of sleep improved, and the patient's capacity for participating in daily life increased.

Consensus points

The key factor in successful cancer pain management is a thorough diagnostic assessment of the contributing pain mechanisms.

This should be supported by effective inter-disciplinary collaboration; better collaboration between pain specialists and oncologists should increase the use of multimodal pharmacotherapy and non-pharmacological treatment.

Choosing an appropriate pharmacological agent and its route of administration are vitally important. Oral administration is the most common and easiest route for most patients with cancer pain. However, the analgesic effect of the agent is largely dependent upon its rate of absorption from the gastrointestinal tract, so pain relief does not begin for 20–30 minutes. Furthermore, bioavailability may be compromised by, for example, emesis and/or first-pass hepatic metabolism. Transdermal patches are non-invasive and can produce steady-state concentrations in 12 hours, while the dose can be increased by simply adding further patches⁵⁷. Side effects may be less when using this route and often limited to local irritation at the site of application^{58,59}, but absorption may be decreased in patients who are cachectic (e.g. by about 50% in the case of fentanyl)⁶⁰, and sweating may cause problems with adhesion (nocturnal hyperhidrosis is a common symptom in cancer patients). Intravenous or subcutaneous administration is usually combined with a patient-controlled analgesia (PCA) device to provide better control over the analgesia than does a continuous infusion⁵⁷. The bioavailability of hydromorphone given subcutaneously has been shown to be approximately 80% in cancer patients, and steady-state plasma concentrations are reached within 24 hours⁶¹.

Administering drugs into the intrathecal space is becoming increasingly popular for treating patients with intractable pain or intolerable side effects from systemic analgesic treatments⁶². The advantages of administration directly into the cerebrospinal fluid include a reduction of systemic side effects and the use of lower drug dosages⁶³. For cancer pain, morphine is the agent most commonly administered via this route, but other opioid and non-opioid drugs are used in this way: for example, hydromorphone, fentanyl, clonidine, or ziconotide⁶². In reviewing studies of intrathecal drug delivery, predominantly with morphine, Smith *et al.* found strong evidence for short-term improvement in cancer pain, and reasonably strong evidence for the use of intrathecal analgesic therapy in long-term cancer pain management⁶⁴. Similarly, intrathecal ziconotide has been shown to provide clinically and

statistically significant analgesia in some patients with refractory cancer pain^{63,65}.

The first choice of analgesic is often a non-opioid; for example, paracetamol or a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen or a cyclooxygenase II (COX II) inhibitor. Non-opioids are effective against pain caused by soft tissue and muscle infiltration, while NSAIDs are particularly useful for treating pain caused by bone metastases. This is because tumor cells often produce a high concentration of prostaglandins in the affected bone, and NSAIDs act partly by blocking prostaglandin biosynthesis⁶⁶. However, some NSAIDs (but not COX II inhibitors) can also delay blood clotting, so may be best avoided in patients receiving anti-cancer drugs that can cause severe thrombocytopenia.

Biophosphonates introduced the concept of disease-modifying therapy for bone metastases, and increasing knowledge of the interaction between cancer cells and the bone matrix has led to the identification of new therapeutic targets^{67,68}. These include compounds and processes involved in cancer-induced bone desorption (e.g. osteoprotegerin, RANK/RANKL interaction), in the metastasis of cancer cells to bone (e.g. Src, nerve growth factor), and also targets on nociceptors that innervate bone (e.g. TPRV1, Trk)^{67,68}.

Opioids are highly effective for treating moderate to severe cancer pain⁶⁹: for example, in conditions such as visceral cancer pain, as well as soft tissue and bone pain, and pain caused by neural compression. Updated guidelines on the use of opioids for treating cancer pain have been issued by the European Association for Palliative Care (EAPC)⁷⁰. Developed according to the Grading of Recommendations Assessment, Development and Evaluation system, the 16 evidence-based recommendations cover such topics as choice of opioid and the treatment of side effects⁷⁰. For example, immediate-release formulations are much more flexible than long-acting preparations, but evidence suggests that immediate-release and extended-release oral formulations of morphine, oxycodone, and hydromorphone can be used for dose titration, supplemented by immediate-release oral opioids as required⁷⁰. Also – possibly as a result of incomplete cross-tolerance – patients receiving opioids who do not achieve adequate analgesia and have severe or unmanageable side-effects may benefit from switching to an alternative opioid⁷⁰. A common barrier to the use of opioids is fear of addiction in both physicians and patients, but this should not prevent their prescription in patients who need them.

In addition, there is an increasing use of adjuvant drugs; these are typically non-opioids that confer analgesic effects in certain medical conditions, but primarily treat conditions that do not involve pain. Examples such as tricyclic antidepressants and anticonvulsants are commonly and successfully used to manage pain in cancer patients⁷¹.

A wide variety of non-intrathecal interventional procedures are available, which can be used alone or in combination. These include epidural drug infusions, sympathetic nervous system blockade, nerve blocks, vertebroplasty and kyphoplasty, as well as more invasive and even destructive neurosurgical procedures⁷². The specific intervention should be determined on an individual basis, taking into account the location and characteristics of the pain, as well as the patient's expectations and life expectancy. Regional analgesic techniques are usually considered first, because they do not compromise neurological integrity, while ablative or neurodestructive procedures – which have a narrow risk–benefit ratio – should be deferred as long as possible⁷².

When patients have incurable, progressive and advanced disease with limited life expectancy, palliative care aims to alleviate the physical and emotional symptoms – as far as possible – during the final phase of life. The main focus is on pain therapy and symptom control. Radiotherapy is effective in treating pain not adequately controlled by analgesics, especially pain arising from skeletal metastases; 50%–80% of patients experience improvement in their pain, and 20%–50% of treated patients have complete pain relief^{73–75}. As life expectancy is limited, radiotherapy schedules should provide maximum short- and long-term patient benefit consistent with minimum associated morbidity and disruption of patients' lives. To this end the relative efficacy of single and multiple treatment fractions have been investigated, but no firm conclusions have been drawn. Common dosage regimens include 30 Gy in 10 fractions, 20 Gy in 5 fractions, and a single fraction of 8 Gy. Palliative care also includes providing psychosocial support to both the patient and relatives, in order to maintain the patient's quality of life and allow him or her to die with dignity. This generally requires co-operation between physicians from various disciplines, nursing staff, and other professions involved in the treatment plan.

Breakthrough cancer pain

Breakthrough cancer pain (BTCP) occurs in patients who have persistent pain (i.e. present for ≥ 12 hours per day) which is stable and adequately controlled by ATC analgesic medication^{76,77}. It comprises a transitory exacerbation that requires assessment and targeted treatment independent of the baseline pain^{76,77}, and is highly prevalent among patients with cancer pain. In one prospective survey, 64% of patients reported BTCP of severe or excruciating intensity⁴⁹. In addition, BTCP predicts more severe pain, pain-related distress and functional impairment, and relatively poor quality of life⁷⁸.

BTCP may be divided into two categories: incident and spontaneous^{77,79}. Incident BTCP is related to a specific identifiable cause which may be volitional (precipitated

by a voluntary act such as walking), non-volitional (precipitated by an involuntary act such as coughing), or procedural (precipitated by a therapeutic intervention such as wound dressing). Spontaneous or idiopathic BTCP occurs unexpectedly and cannot be predicted. It should be noted that end of dose pain is not BTCP; it is caused by declining analgesic levels and indicates that the ATC analgesic medication should be re-assessed⁷⁷.

The pathophysiology of BTCP can be nociceptive, neuropathic, or a combination of the two – often it is the same as that of the underlying persistent pain. Differentiating the causative mechanisms involved may be difficult, but peripheral and/or central sensitization may play a major role, initiated by mechanical stimuli, changing chemical environments, and release of tumor growth factors⁸⁰. Although highly variable in character, BTCP is typically rapid in onset, moderate to severe in intensity, and relatively short in duration⁸¹. In 163 oncology patients receiving palliative care who experienced BTCP, 31% of episodes lasted <15 minutes, 64% lasted <30 minutes, and 87% lasted <60 minutes⁸². The mean intensity was 7.3 on a 10 cm Visual Analogue Scale (VAS), compared with 2.9 for persistent pain⁸². Other studies have found the mean incidence to be four episodes per day, with a mean duration of 30 minutes each (range 1–240 minutes)⁴⁹, and the median time from onset to peak intensity to be 3 minutes (range 1 second to 30 minutes)⁸¹. Although BTCP follows a circadian pattern⁸³, there is considerable variability in duration and intensity from one patient to another, and from one episode to another in an individual patient.

BTCP is under-diagnosed and under-treated. In one study of patients with advanced cancer who participated in a palliative home care program, only 32% were receiving medication for BTCP on admission to the program, and 67% of the survivors 1 month later⁸⁴. There are various reasons for this. Firstly, BTCP is a complex phenomenon which is dependent upon the stage of the disease, the individual patient, and therapeutic factors⁸⁴. Secondly, the phenomenon is often not fully understood by healthcare professionals so that patient assessment is poor, and thirdly, there is often a reluctance to prescribe opioids because of cultural or regulatory factors, or concerns about side effects.

Moreover, even when BTCP is treated, the most appropriate analgesic is not always prescribed. For example, one study reported that the median time to peak intensity of pain was 10 minutes (range <1 minute to 240 minutes) and the median duration of untreated episodes was 60 minutes (range <1 minute to 360 minutes), although the variability between patients was considerable⁸⁵. Many patients, however, are treated with oral opioids, for which the onset of analgesia takes at least 20–30 minutes and the peak effect is not experienced for 60–90 minutes⁸⁶. Ideally, treatments for BTCP should

have a rapid onset, short duration (1–2 hours), and sufficient analgesic potency to relieve severe pain. Intravenous or subcutaneous patient-controlled analgesia (PCA) pumps come close to matching these criteria for hospitalized patients, but may not be practical for outpatients⁷⁶.

Transmucosal rapid-onset opioids (fast-acting fentanyl formulations) – such as oral fentanyl citrate (OTFC) sublingual tablets⁸⁷, the effervescent fentanyl buccal tablet (FBT)^{88,89} and the intranasal fentanyl spray (INFS)^{90,91} – utilize novel formulations to produce an onset of analgesia often ≤ 15 minutes, making them suitable for BTCP episodes with a rapid or unpredictable onset. Maximum plasma concentrations are reached after median times of 91 minutes (OTFC)⁸⁹, 30–60 minutes (transmucosal fentanyl tablets)⁹², 47 minutes (FBT)⁸⁹ and 12–15 minutes (INFS)⁹¹. Fentanyl is highly potent because of its lipophilicity and has no ceiling effect, i.e. analgesia is proportional to the dose. When used to treat BTCP, OTFC gives lower pain intensity scores and higher pain relief scores than placebo and morphine at all time points⁹³. Similarly, randomized clinical trials have shown FBT and INFS to be efficacious and well tolerated, with a rapid onset of analgesia (within 10 minutes) and sustained effect^{88,90,91}. A systematic review of the use of opioids for managing breakthrough pain in patients with cancer found that transmucosal and parenteral opioids were equally effective after 30 minutes⁹⁴, but one study which compared OTFC with oral morphine found the latter to be an inferior comparator⁹⁵.

These properties have been taken into consideration by recent guidelines, such as those produced by the European Association for Palliative Care⁷⁰. These state “In some cases the buccal or intranasal fentanyl preparations are preferable to immediate-release oral opioids because of more-rapid onset of action and shorter duration of effect. Additionally, the data permit a weak recommendation that immediate-release formulations of opioids with short half-lives should be used to treat pre-emptively predictable episodes of breakthrough pain in the 20–30 min preceding the provoking manoeuvre.” The different fentanyl formulations vary in pharmacokinetic properties and ease of use, but all of them have a rapid onset and a relatively short duration of analgesia. It should be noted that fast-acting fentanyl formulations are only indicated for the treatment of BTCP, and not as supplemental opioid therapy to address circadian variations in pain intensity.

Consensus point

Fast-acting transmucosal fentanyl formulations are considered a more appropriate choice for treating breakthrough cancer pain with a rapid or unpredictable onset.

Chemotherapy-induced neuropathic pain

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse effect of many chemotherapeutic agents that affects 30–40% of patients receiving chemotherapy⁹⁶. The incidence and severity depend upon the type of cytotoxic drug(s), duration of administration, cumulative dose, pharmacogenetics and presence of any pre-existing peripheral neuropathy. Classes of agent which can cause CIPN include platinum compounds, taxanes, vinca alkaloids, thalidomide and bortezomib. The intensity of pain is generally mild, with other symptoms being more prominent, but it may be debilitating and reduce the quality of life of the patient. Recent research indicates that satellite glial cells in dorsal root ganglia are activated by cytotoxic agents, which leads to increased gap junction-mediated coupling between these cells and lowering of the pain threshold⁹⁷.

The precise mechanism by which platinum compounds induce CIPN remains unclear⁹⁶. Neuropathy due to cisplatin is usually reversible, typically appears 3–6 months after treatment starts and continues after discontinuation of treatment. Symptoms are predominantly sensory and include paresthesias, loss of vibration sense, and decreased tendon reflexes⁹⁶. Between 85% and 95% of patients receiving oxaliplatin develop sensory neuropathy, which presents as two different types of neurotoxicity⁹⁸. Shortly after infusion, most recipients develop an acute, mainly cold-triggered neuropathy with distal paresthesias, dysesthesias, and mild muscle contractions of the hands, feet and perioral region⁹⁶. This is followed by a chronic sensory neuropathy with diminished or absent proprioception, vibration, touch, two-point discrimination, sharp/dull discrimination, temperature, and touch/pain, typically in a stocking-glove distribution^{96,99}. In approximately one-third of patients, symptoms disappear completely in 6–8 months.

In some patients receiving the taxane paclitaxel, a cumulative, dose-dependent, painful neuropathy with burning pain and hyperalgesia develops 24 to 72 hours after administration¹⁰⁰. Docetaxel produces CIPN much less frequently than paclitaxel (1–9% vs. 30%)⁹⁶, with mild symptoms that usually disappear spontaneously after discontinuation. Vinca alkaloids, of which vincristine is the most toxic, induce alterations in the cellular microtubuli structure and disrupt the axonal flow⁹⁶, causing a painful sensory neuropathy and, in some patients, autonomic dysfunction. The changes produced are usually reversible on discontinuation, but recovery may be slow. Other chemotherapeutic agents which may cause CIPN include thalidomide and bortezomib.

Any candidate chemoprotective agent must fulfill certain criteria: it must prevent or mitigate the CIPN associated with chemotherapy without interfering with

the antitumor activity of cytotoxic agents, and be devoid of significant toxicity itself¹⁰¹. In a prospective, randomized, double-blind, placebo-controlled crossover trial, the serotonin–norepinephrine reuptake inhibitor duloxetine significantly reduced the average pain score (mean decrease 1.06 vs. 0.34 for placebo; $p=0.03$) in patients with painful CIPN following paclitaxel, other taxane, or oxaliplatin treatment¹⁰². A similar study evaluated venlafaxine for the prevention and relief of acute neurotoxicity caused by oxaliplatin, and found this agent significantly reduced symptoms compared with placebo (full relief achieved by 31.3% vs. 5.3%; $p=0.03$), whilst having an acceptable toxicity profile¹⁰³. Topical treatment with a baclofen/amitriptyline/ketamine gel has demonstrated a trend for improving CIPN symptoms – without evident systemic toxicity – in a double-blind, randomized, placebo-controlled clinical trial¹⁰⁴, but further research is needed with higher doses. Promising results have also been obtained in a pilot study of patient-specific cutaneous electrostimulation in patients with CIPN following treatment with taxanes, platinum drugs or bortezomib¹⁰⁵. The mean NRS pain score fell by 59% over the course of 10 days' treatment ($p<0.0001$), and a reduction of $>20\%$ was achieved by 94% of the patients ($p<0.0001$)¹⁰⁵.

Tricyclic antidepressants are often used to treat CIPN and have been reported to relieve the paresthesia associated with peripheral neuropathies. However, in a phase III study to evaluate the alleviation of symptoms of cisplatin-induced CIPN, nortriptyline increased patients' hours of sleep but its effect on paresthesia was modest at best, and there was no significant improvement in quality of life or daily activities¹⁰⁶. Similar results have been obtained for amitriptyline¹⁰⁷.

At the present time, preventative treatment should be limited to patients at high risk of developing CIPN (e.g. with diabetes, hypothyroidism, or a diagnosed neuropathy) but this may change as more data are acquired on potential agents such as TRPA1 (ankyrin) antagonists, topical menthol, and antioxidants such as acetyl-L-carnitine^{108–110}.

Pain-related problems after cancer

Increasing numbers of patients are clear of cancer following treatment, but often experience chronic pain syndromes on the completion of treatment. Others are not cured, but remain in a chronic, stable disease state for many years. There is a lack of scientific evidence and clinical guidelines for the management of these patients, and optimal pain relief is hindered by barriers such as fear of side effects, lack of professional knowledge of pain management, lack of timely access to pain medication and fear of addiction.

Various studies have estimated the prevalence of opioid addiction in cancer patients to be between 0% and 7.7%¹¹¹. The literature suggests that there is no single predictor or tool capable of identifying patients likely to misuse opioid medication, but certain patient characteristics such as younger age, anxiety, fatigue and depression are associated with greater risk¹¹². Known risk factors should be identified and monitored in order to detect misuse; for example, by completing a Screener for Opioid Assessment for Patients with Pain–Short Form (SOAPP–SF), establishing an opioid agreement and obtaining a psychological evaluation¹¹². However, it is difficult to differentiate between inadequate analgesia (pseudoaddiction), addiction, and use of opioids as an emotional coping strategy¹¹³. Misuse increases the complexity of pain management, and unchecked addiction can lead to impaired quality of life, decreased pain control, and caregiver stress¹¹⁴. The risk of abuse may be greater for fast-acting fentanyl than other formulations, owing to their rapid onset of effect. Many hospice and palliative care physicians report having had very little training in this field, and survey results suggest that additional postgraduate training focusing on opioid misuse might prove beneficial¹¹³.

Pain management programs which take cognitive and behavioral principles into account are the treatment of choice, delivered by a multidisciplinary team working in an interdisciplinary way¹¹⁵. This team should include a pain specialist as well as a clinical psychologist, pain should be taken into consideration from the beginning of treatment, and team members should be closely acquainted with each others' roles and responsibilities.

Conclusions

Pain is the most common reason for consulting a health-care professional that leads to a cancer diagnosis and its effect on patients' quality of life can be devastating, but the treatment of cancer pain is often suboptimal. Almost three-quarters of cancer patients experience pain, but almost a quarter of those with moderate to severe pain do not receive any analgesic medication and more than a fifth are never, or only occasionally, asked about their pain.

General principles for treating cancer pain include the immediate relief of acute pain and preventing the development of chronic pain. A multidisciplinary approach and the choice of an appropriate pharmacological agent are vital. Two particular challenges are BTCP and CIPN. Treatments for BTCP should have a rapid onset, short duration, and sufficient analgesic potency to relieve severe pain – fast-acting fentanyl formulations meet these criteria and are suitable for BTCP episodes with a rapid or unpredictable onset. CIPN is a dose-limiting

adverse effect of many chemotherapeutic agents. Several potential neuroprotective agents have been investigated, and duloxetine or venlafaxine significantly reduce CIPN symptoms, but preventative treatment should currently be limited to patients at high risk of developing the condition.

Addressing the unmet needs of cancer pain patients will depend largely upon improving medical education, both at undergraduate and postgraduate level. There should be greater emphasis upon pain management at undergraduate level¹¹⁶, a change of focus from symptom control to mechanism-based, multi-modal therapy, and more encouragement for healthcare professionals to participate in Continuing Medical Education related to pain and analgesia, such as the PAIN EDUCATION Program which is an integral part of the CHANGE PAIN initiative.

Transparency

Declaration of funding

Funding for this study was provided by Grünenthal GmbH.

Declaration of financial/other relationships

G.M.-S., K.A., D.A., E.A., S.C., F.C., F.H., W.J., E.K., M.K.-K., H.-G.K., A.C.M., C.M.F., B.M., A.N., C.P.H., J.P., M.S., and P.S. have disclosed that they are members of the CHANGE PAIN International Advisory Board; as such, they have received honoraria for attending the meetings upon which this paper is based. In addition, H.-G.K. and G.M.-S. have disclosed that they are chairmen of the International Advisory Board on CHANGE PAIN for Grünenthal GmbH, and receive honoraria in this context. None of the authors received honoraria for the writing of this paper.

CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgments

Medical writing support was provided by Derrick Garwood of Derrick Garwood Ltd, Cambridge, UK, and was funded by Grünenthal GmbH.

References

- Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. *Ann Oncol* 2009;20:1420-33
- Pharo GH, Zhou L. Pharmacologic management of cancer pain. *J Am Osteopath Assoc* 2005;105(11 Suppl 5):S21-8
- European Society for Medical Oncology Minimum Clinical Recommendations for the management of cancer pain. *Ann Oncol* 2005;16(Suppl 1):i83-i85
- Foley KM. How well is cancer pain treated? *Palliat Med* 2011;25:398-401
- Lin C-C, Lai Y-L, Ward SE. Effect of cancer pain on performance status, mood states, and level of hope among Taiwanese cancer patients. *J Pain Symptom Manage* 2003;25:29-37
- World Health Organization. *Cancer Pain Relief*. Geneva: World Health Organization, 1986
- Hsieh RK. Pain control in Taiwanese patients with cancer: a multicenter, patient-oriented survey. *J Formos Med Assoc* 2005;104:913-19
- Kuo PY, Yen JTC, Parker GM, et al. The prevalence of pain in patients attending sarcoma outpatient clinics. *Sarcoma* 2011;2011:813483
- Fisch MJ, Lee J-W, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. *J Clin Oncol* 2012;30:1980-8
- Lodish H, Berk A, Zipursky SL, et al. *Molecular Cell Biology*, 4th edn. New York: W.H. Freeman, 2000
- Schmidt BL, Hamamoto DT, Simone DA, Wilcox GL. Mechanism of cancer pain. *Mol Interv* 2010;10:164-78
- Gokin AP, Fareed MU, Pan HL, et al. Local injection of endothelin-1 produces pain-like behavior and excitation of nociceptors in rats. *J Neurosci* 2001;21:5358-66
- Hans G, Deseure K, Robert D, De Hert S. Neurosensory changes in a human model of endothelin-1 induced pain: a behavioral study. *Neurosci Lett* 2007;418:117-21
- Davar G. Endothelin-1 and metastatic cancer pain. *Pain Med* 2001;2:24-7
- Bortsov AV, Millikan RC, Belfer I, et al. μ -opioid receptor gene Aa118G polymorphism predicts survival in patients with breast cancer. *Anesthesiology* 2012;116:896-902
- Barki-Harrington L, Daaka Y. Bradykinin induced mitogenesis of androgen independent prostate cancer cells. *J Urol* 2001;165:2121-5
- Fujita M, Andoh T, Ohashi K, et al. Roles of kinin B1 and B2 receptors in skin cancer pain produced by orthotopic melanoma inoculation in mice. *Eur J Pain* 2010;14:588-94
- Andoh T, Akira A, Saiki I, Kuraishi Y. Bradykinin increases the secretion and expression of endothelin-1 through kinin B2 receptors in melanoma cells. *Peptides* 2010;31:238-41
- Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. *Br J Pharmacol* 1997;121:417-24
- Wacnik PW, Eikmeier LJ, Simone DA, et al. Nociceptive characteristics of tumor necrosis factor-alpha in naive and tumor-bearing mice. *Neuroscience* 2005;132:479-91
- Constantin CE, Mair N, Sailer CA, et al. Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. *J Neurosci* 2008;28:5072-81
- Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis* 2009;30:1073-81
- Zhu Z, Friess H, diMola FF, et al. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. *J Clin Oncol* 1999;17:2419-28
- Ma J, Jiang Y, Jiang Y, et al. Expression of nerve growth factor and tyrosine kinase receptor A and correlation with perineural invasion in pancreatic cancer. *J Gastroenterol Hepatol* 2008;23:1852-9
- Kolokythas A, Cox DP, Dekker N, Schmidt BL. Nerve growth factor and tyrosine kinase A receptor in oral squamous cell carcinoma: is there an association with perineural invasion? *J Oral Maxillofac Surg* 2010;68:1290-5
- Shen F-Z, Zhang B-Y, Feng Y-J, et al. Current research in perineural invasion of cholangiocarcinoma. *J Exp Clin Canc Res* 2010;29:24
- Johnston M, Yu E, Kim J. Perineural invasion and spread in head and neck cancer. *Expert Rev Anticancer Ther* 2012;12:359-71
- Liebig C, Ayala G, Wilks JA, et al. Perineural invasion in cancer. *Cancer* 2009;115:3379-91
- Mercadante S. Malignant bone pain: pathophysiology and treatment. *Pain* 1997;69:1-18
- Koutsilieris M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. *Crit Rev Oncol Hematol* 1995;18:51-64
- Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. *JAMA* 1999;281:1591-7

32. Msaouel P, Pissimissis N, Halapas A, et al. Mechanisms of bone metastasis in prostate cancer: clinical implications. *Best Pract Res Clin Endocrinol Metab* 2008;22:341-55
33. Vakaet LAM-L, Boterberg T. Pain control by ionizing radiation of bone metastasis. *Int J Dev Biol* 2004;48:599-606
34. Smith HJ. Painful osseous metastases. *Pain Physician* 2011;14:E373-405
35. Cain DM, Wacnik PW, Turner M, et al. Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. *J Neurosci* 2001;21:9367-76
36. Yanagisawa Y, Furue H, Kawamata T, et al. Bone cancer induces a unique central sensitization through synaptic changes in a wide area of the spinal cord. *Molecular Pain* 2010;6:38
37. Woolf CJ. What is this thing called pain? *J Clin Invest* 2010;120:3742-4
38. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. *Ann Intern Med* 2004;140:441-51
39. Forde G. Adjuvant analgesics for the treatment of neuropathic pain: evaluating efficacy and safety profiles. *J Fam Pract* 2007;56:3-12
40. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. *Neurology* 2008;70:1630-5
41. Morlion B. Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components. *Curr Med Res Opin* 2011;27:11-33
42. Schenk M, Urnauer H, Schug SA, et al. Cancer Pain. In: Spies C, Schug SA, Jaehnicen G, et al, eds. *Pocket Guide Pain Management*. Berlin Heidelberg: Springer-Verlag, 2008:67-79
43. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. *Ann Oncol* 2008;19:1985-91
44. Rustøen T, Moum T, Padilla G, et al. Predictors of quality of life in oncology outpatients with pain from bone metastasis. *J Pain Symptom Manage* 2005;30:234-42
45. Mantyh P. Bone cancer pain: causes, consequences, and therapeutic opportunities. *Pain* 2013;154(Suppl 1):S54-62
46. Portenoy RK. Treatment of cancer pain. *Lancet* 2011;377:2236-47
47. Fainsinger RL, Nekolaichuk C, Lawlor P, et al. An international multicentre validation study of a pain classification system for cancer patients. *Eur J Cancer* 2010;46:2896-904
48. Lasheen W, Walsh D, Sarhill N, Davis M. Intermittent cancer pain: clinical importance and an updated cancer pain classification. *Am J Hosp Palliat Care* 2010;27:182-6
49. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. *Pain* 1990;41:273-81
50. Margarit C, Juliá J, López R, et al. Breakthrough cancer pain – still a challenge. *J Pain Res* 2012;5:559-66
51. Breuer B, Fleishman SB, Cruciani RA, et al. Medical oncologists' attitudes and practice in cancer pain management: a national survey. *J Clin Oncol* 2011;29:4769-75
52. Stockler MR, Wilken NRC. Why is management of cancer pain still a problem? *J Clin Oncol* 2012;30:1907-8
53. Peng WL, Wu GJ, Sun WZ, et al. Multidisciplinary management of cancer pain: a longitudinal retrospective study on a cohort of end-stage cancer patients. *J Pain Symptom Manage* 2006;32:444-52
54. Buga S, Sarria JE. The management of pain in metastatic bone disease. *Cancer Control* 2012;19:154-66
55. Varrassi G, Müller-Schwefe G, Pergolizzi J, et al. Pharmacological treatment for chronic pain – the need for CHANGE. *Curr Med Res Opin* 2010;26:1055-69
56. Müller-Schwefe G, Jaksch W, Morlion B, et al. Make a CHANGE: optimising communication and pain management decisions. *Curr Med Res Opin* 2010;27:481-8
57. Stevens RA, Ghazi SM. Routes of opioid analgesic therapy in the management of cancer pain. *Cancer Control* 2000;7(2):132-41
58. Kress HG, von der Laage D, Hoerauf KH, et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. *J Pain Symptom Manage* 2008;36:268-79
59. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. *Eur J Pain* 2009;13:219-30
60. Heiskanen T, Mätzke S, Haakana S, et al. Transdermal fentanyl in cachectic cancer patients. *Pain* 2009;144:218-22
61. Moulin DE, Kreeft JH, Murray-Parsons N, et al. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. *Lancet* 1991;337:465-8
62. Kress HG, Simpson KH, Marchettini P, et al. Intrathecal therapy: what has changed with the introduction of ziconotide. *Pain Pract* 2009;9:338-47
63. Raffaelli W, Sarti D, Demartini L, et al; and Italian Ziconotide Group. Italian registry on long-term intrathecal ziconotide treatment. *Pain Phys* 2011;14:15-24
64. Smith HS, Deer TR, Singh V, et al. Intrathecal drug delivery. *Pain Phys* 2008;11:S89-104
65. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. *JAMA* 2004;291:63-70
66. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. *Pharmacol Rev* 2004;56:387-437
67. Coluzzi F, Di Bussolo E, Mandatori I, Mattia C. Bone metastatic disease: taking aim at new therapeutic targets. *Curr Med Chem* 2011;18:3093-115
68. Coluzzi F, Mandatori I, Mattia C. Emerging therapies in metastatic bone pain. *Expert Opin Emerg Drugs* 2011;16:441-58
69. National Cancer Institute at the National Institutes of Health. Management with Drugs. Last updated 27th February 2012. Available at: <http://www.cancer.gov/cancertopics/pdq/supportivecare/pain/Patient/page4> [Last accessed 4 April 2013]
70. Caraceni A, Hanks G, Kaasa S, et al; on behalf of the European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. *Lancet Oncol* 2012;13:e58-68
71. Christo PJ, Mazloomdoost D. Cancer pain and analgesia. *Ann NY Acad Sci* 2008;1138:278-98
72. Tay W, Ho KY. The role of interventional therapies in cancer pain management. *Ann Acad Med Singapore* 2009;38:989-97
73. Bates T. A review of local radiotherapy in the treatment of bone metastases and cord compression. *Int J Radiat Oncol Biol Phys* 1992;23:217-21
74. Maher EJ. The use of palliative radiotherapy in the management of breast cancer. *Eur J Cancer* 1992;28:706-10
75. Bae SH, Park W, Choi DH, et al. Palliative radiotherapy in patients with a symptomatic pelvic mass of metastatic colorectal cancer. *Radiation Oncology* 2011;6:52
76. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: management. *Pharm Ther* 2005;30:354-61
77. Davies AN, Dickman A, Reid C, et al. The management of cancer-related break-through pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. *Eur J Pain* 2009;13:331-8
78. Caraceni A, Martini C, Zecca E, Portenoy RK. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. *Palliat Med* 2004;18:177-83
79. Davies A. Current thinking in cancer breakthrough pain management. *Eur J Palliat Care* 2005;12(Suppl):4-6
80. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. *Eur J Pain* 2005;9:195-206
81. Portenoy RK, Payne D, Jacobson P. Breakthrough pain: characteristics and impact in patients with cancer pain. *Pain* 1999;81:129-34

82. Gómez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. *J Pain Symptom Manage* 2002;24:45-52
83. Saini A, Tucci M, Tampellini M, et al. Circadian variation of breakthrough pain in cancer patients. *Eur J Pain* 2012; published online 19 June 2012, doi: 10.1002/j.1532-2149.2012.00184.x
84. Mercadante S, Costanzo BV, Fusco F, et al. Breakthrough pain in advanced cancer patients followed at home: a longitudinal study. *J Pain Symptom Manage* 2009;38:554-60
85. Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. *J Pain Symptom Manage* 2013;46:619-28
86. Davies A, Vriens J, Kennett A, McTaggart M. An observational study of oncology patients' utilization of breakthrough pain medication. *J Pain Symptom Manage* 2008;35:406-11
87. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. *Curr Med Res Opin* 2009;25:2877-85
88. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. *J Support Oncol* 2007;5:327-34
89. Darwish M, Kirby M, Robertson P, et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. *J Clin Pharmacol* 2007;47:343-50
90. Kress HG, Orońska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 µg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. *Clin Ther* 2009;31:1177-91
91. Kaasa S, Moksnes K, Nolte T, et al. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. *J Opioid Manage* 2010;6:17-26
92. Twycross R, Prommer EE, Mihalyo M, Wilcock A. Fentanyl (transmucosal). *J Pain Symptom Manage* 2012;44:131-49
93. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. *Cochrane Database Syst Rev* 2006;(1):CD004311
94. Zeppetella G. Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project. *Palliative Med* 2001;25:516-24
95. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). *Pain* 2001;91:123-30
96. Beijers AJM, Jongen JLM, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. *Neth J Med* 2012;70:18-25
97. Warwick RA, Hanani M. The contribution of satellite glial cells to chemotherapy-induced neuropathic pain. *Eur J Pain* 2013;17:571-80
98. Kweekel DM, Gelderblom H, Guchelaar H-J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. *Cancer Treat Rev* 2005;31:90-105
99. Hausheer FH, Schilsky RL, Bain S, et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. *Semin Oncol* 2006;33:15-49
100. Balaysac D, Ferrier J, Descœur J, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. *Expert Opin Drug Saf* 2011;10:407-17
101. Hausheer FH, Kochat H, Parker AR, et al. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. *Cancer Chemother Pharmacol* 2003;52(Suppl):S3-15
102. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. *JAMA* 2013;309:1359-67
103. Durand JP, Deplanque G, Montheil V, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. *Ann Oncol* 2011;23:200-5
104. Barton DL, Wos EJ, Qin R, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCTG trial N06CA. *Support Care Cancer* 2011;19:833-41
105. Smith TJ, Coyne PJ, Parker GL, et al. Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare) for chemotherapy-induced peripheral neuropathy. *J Pain Symptom Manage* 2010;40:883-91
106. Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. *Pain* 2002;98:195-203
107. Kautio AL, Haanpää M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. *J Pain Symptom Manage* 2008;35:31-9
108. Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. *Eur J Cancer* 2005;41:1746-50
109. Storey DJ, Colvin LA, Scott AC, et al. Treatment of chemotherapy-induced peripheral neuropathy (CIPN) with topical menthol: a phase I study. *J Clin Oncol* 2010;28(15):Suppl 9129
110. Nassini R, Benemei S, Fusi C, et al. Transient receptor potential channels in chemotherapy-induced neuropathy. *Open Pain J* 2013;6(Suppl 1):127-36
111. Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: a literature review. *Eur J Pain* 2007;11:490-518
112. Koyyalagunta D, Bruera E, Aigner C, et al. Risk stratification of opioid misuse among patients with cancer pain using the SOAPP-SF. *Pain Med* 2013;14:667-75
113. Childers JW, Arnold RM. "I feel uncomfortable 'calling a patient out'": Educational needs of palliative medicine fellows in managing opioid misuse. *J Pain Symptom Manage* 2012;43:253-60
114. Passik SD, Theobald DE. Managing addiction in advanced cancer patients: why bother? *J Pain Symptom Manage* 2000;19:229-34
115. Turk DC, Stieg RL. Chronic pain: the necessity of interdisciplinary communication. *Clin J Pain* 1987;3:163-7
116. Kress HG. The importance of putting pain on the curricula in medical schools in Europe. *J Pain Palliat Care Pharmacother* 2013;27:182-4